Close Menu

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market on Monday that its fourth quarter revenues grew 32 percent year over year and beat the consensus Wall Street estimate.

For the three months ended Dec. 31, 2018, the South San Francisco, California-based genomics diagnostics firm posed $25.8 million in revenues, up from $19.6 million in Q4 2017 and above analysts' average estimate of $24.4 million.

Total genomic test volume was up 28 percent year over year to 9,154 tests in the quarter, Veracyte said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.